We reviewed the clinical and neuroimaging findings of seven patients presented at our institution with white matter hyperintensities and neurologic complications during treatment of hematologic malignancies. The studies were performed on a 1.5 T MR unit of our hospital. We reviewed the clinical and radiologic findings of seven patients methotrextae related neurotoxicity during or after treatment with intrathecal methotrexate.
![](https://epos.myesr.org/posterimage/esr/ecr2006/736/media/10805?maxheight=300&maxwidth=300)
Fig.: Cranial CT does not demonstrate abnormal findings in white matter of centrum semiovale
![](https://epos.myesr.org/posterimage/esr/ecr2006/736/media/3544?maxheight=300&maxwidth=300)
Fig.: MRI study performed during the acute onset of symptoms in acute methotrexate neurotoxicity.
![](https://epos.myesr.org/posterimage/esr/ecr2006/736/media/16411?maxheight=300&maxwidth=300)
Fig.: 4-y-old child with Acute lymphoid leukemia who suffered a subacute methotrexate neurotoxicity. MRI shows hyperintensities in deep white matter of both parietal and temporal lobes.
![](https://epos.myesr.org/posterimage/esr/ecr2006/736/media/16390?maxheight=300&maxwidth=300)
Fig.: Follow-up of a 4-y-old child who had suffered 2 months ago an acute methotrexate leukoencephalopathy. T2 shows persistence of hyperintense areas in deep white matter, and normalization of DWI image, with slight increase on ADC map.